Health ❯ Patient Care ❯ Treatment Outcomes ❯ Clinical Research

FDA Approval Process

Gene Therapy Slows Huntington’s Progression by 75% in Early Trial, uniQure Says

The one-time, neurosurgically delivered treatment showed three-year benefits in a 29-patient Phase 1/2 study, with full data to be presented next month and an FDA filing targeted for early 2026.